

Q-linea announces the initiation of a DOOR MAT study at a large US academic medical center

Q-linea AB (publ) (OMX:QLINEA) today announces the initiation of a DOOR MAT study, a first of its kind using the ASTar® instrument.

A Desirability of Outcome Ranking Approach for the Management of Antimicrobial Therapy (DOOR MAT) analysis balances patient outcomes and antimicrobial stewardship goals.

The study will be conducted at a large academic center on the US east coast and will complement existing and ongoing analytical and health economics studies, adding to the growing body of evidence of the impacts of the ASTar system. Study authors anticipate that the use of rapid antibiotic susceptibility test results will lead to a hypothetical reduction in days of broad spectrum and inappropriate antibiotic therapy when retrospective chart analyses are completed.

“We are proud of our research collaborations with leading institutions in the US that are paving the way for broad adoption of rapid AST. We already have strong evidence of ASTar benefits to patients from our European partners, and this study will provide additional US-specific outcomes and impact data from ASTar in a clinical setting”, says Stuart Gander, CEO for Q-linea.

More information on ASTar outcomes can be found here: https://qlinea.com/0986741_wp-uploads/2024/08/D84524-Poster-ESCMID-Global-HEOR-Interim.pdf

For more information, please contact:

Stuart Gander, President & CEO, Q-linea

Stuart.Gander@qlinea.com

+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB

Christer.Samuelsson@qlinea.com

+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

Q-linea announces the initiation of a DOOR MAT study at a large US academic medical center